A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV
Our results collectively support the candidacy of recombinant rTTV-RBD-HA2 as a novel respiratory virus vaccine that provides cross-protection against coronaviruses and influenza viruses, surpassing the breadth of previous vaccines. Additionally, they underscore the importance of establishing a strong mucosal T cell response in the development of a universal respiratory virus vaccine.
Authors
- Cuisong Zhu (ORCID: https://orcid.org/0000-0003-3659-1466)
- Jianqing Xu (ORCID: https://orcid.org/0000-0003-0896-9273)
- Nan Gao (ORCID: https://orcid.org/0000-0003-0259-3316)
- Haoran Peng (ORCID: https://orcid.org/0000-0002-7862-1013)
- Longfei Ding (ORCID: https://orcid.org/0000-0002-7660-0876)
- Kangli Cao
- Wanda Tang
- Ai Xia (ORCID: https://orcid.org/0000-0003-0373-9196)
- Shimeng Bai (ORCID: https://orcid.org/0000-0003-4020-1934)
- Youwei Zhu
- Chen Zhao (ORCID: https://orcid.org/0000-0002-0718-7707)
- Lanlan Dong (ORCID: https://orcid.org/0000-0003-2565-9437)
- Tianhan Yang
- Xiaoyan Zhang (ORCID: https://orcid.org/0000-0001-6892-1082)
Institutions
- Second Military Medical University (CN)
- Xiamen University (CN)
- Fudan University (CN)
- Southern University of Science and Technology (CN)
- Shanghai Public Health Clinical Center (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- Shenzhen Third People’s Hospital (CN)
- Xiamen University of Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3389/fimmu.2024.1473428
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Peking University
- Tianjin Medical University
- National Key Research and Development Program of China